Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Tarih
2021
Yazar
Gladkov, O.
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Makharadze, T.
Paydas, S.
Nechaeva, M.
Seebach, F.
Weinreich, D. M.
Yancopoulos, G. D.
Gullo, G.
Lowy, I.
Rietschel, P.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/171524
Koleksiyonlar